A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE
Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | MRL Ventur... | mrlv.com |
| - | SV Health ... | svhealthin... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKerna... | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investo... | svhealthin... |
| 21.11.2023 | Dementia Discovery Fund Announces the Acquisition of Caraway... | This transaction highlights DDF’s attractive strategy of investing in novel therapeutics for dementi... | svhealthin... |
| 09.06.2021 | Caraway Therapeutics Establishes Collaboration with AbbVie t... | CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and ... | svhealthin... |
| 09.06.2021 | The Dementia Discovery Fund’s Portfolio Company Caraway Ther... | Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to anno... | svhealthin... |